sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks N-[(8R)-1-azabicyclo[2.2.2]oct-8-yl]-2-oxo-9-thia-5-azabicyclo[4.3.0]n ona-3,7,10-triene-3-carboxamide hydrochloride

N-[(8R)-1-azabicyclo[2.2.2]oct-8-yl]-2-oxo-9-thia-5-azabicyclo[4.3.0]n ona-3,7,10-triene-3-carboxamide hydrochloride

CAS No.:
194093-42-0
Catalog Number:
AG00BB7T
Molecular Formula:
C15H18ClN3O2S
Molecular Weight:
339.8403
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$223
- +
10mg
99%
1 week
United States
$340
- +
25mg
99%
1 week
United States
$707
- +
50mg
99%
1 week
United States
$1223
- +
100mg
99%
1 week
United States
$2057
- +
Product Description
Catalog Number:
AG00BB7T
Chemical Name:
N-[(8R)-1-azabicyclo[2.2.2]oct-8-yl]-2-oxo-9-thia-5-azabicyclo[4.3.0]n ona-3,7,10-triene-3-carboxamide hydrochloride
CAS Number:
194093-42-0
Molecular Formula:
C15H18ClN3O2S
Molecular Weight:
339.8403
MDL Number:
MFCD00939557
IUPAC Name:
N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide;hydrochloride
InChI:
InChI=1S/C15H17N3O2S.ClH/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18;/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20);1H/t12-;/m0./s1
InChI Key:
XGVADZZDFADEOO-YDALLXLXSA-N
SMILES:
O=C(c1c[nH]c2c(c1=O)scc2)N[C@H]1CN2CCC1CC2.Cl
UNII:
UVW44TKU66
Properties
Complexity:
499  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
339.081g/mol
Formal Charge:
0
Heavy Atom Count:
22  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
339.838g/mol
Monoisotopic Mass:
339.081g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
89.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae. Life sciences 20120409
Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract. Pharmacology 20080101
Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Current opinion in investigational drugs (London, England : 2000) 20070501
Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. Journal of clinical pharmacy and therapeutics 20051201
Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Alimentary pharmacology & therapeutics 20031115
Properties